IP Library › Patent Application 12070981
Patent Application
App. No. 12/070,981

Methods for treating rheumatoid arthritis using IL-17 antagonists

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/070,981
Abstract

A method of treating a mammal afflicted with rheumatoid arthritis comprising administering a soluble form of IL-17 receptor is disclosed.

Claims (5)

1 . A method of treating an individual afflicted with rheumatoid arthritis, the method comprising administering to said individual an antibody that specifically binds Interleukin-17, wherein said antibody inhibits Interleukin-17 receptor signal transduction.

2 . The method of claim 1 , further comprising administering one or more therapeutics selected from the group consisting of TNF antagonist, IL-1 antagonist and DMARD.

3 . The method of claim 2 wherein the TNF antagonist is selected from the group consisting of TNF antibodies, soluble TNF receptor p75, and soluble TNF receptor p55.

4 . The method of claim 2 wherein the IL-1 antagonist is selected from the group consisting of soluble IL-1 receptor type II, IL-1R type I antibody, IL-1 receptor antagonist, and fusion protein comprising soluble IL-1 receptor type I, and soluble IL-1 receptor accessory protein.

5 . The method of claim 2 wherein the DMARD is methotrexate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2013
From: AMGEN INC.
To: KIRIN-AMGEN, INC.
Reel/Frame 030045/0876 →